Download PDF
Pneumologie 2006; 60(11): 679-693
DOI: 10.1055/s-2006-932219
Fort- und Weiterbildung
© Georg Thieme Verlag Stuttgart · New York

Die chronisch obstruktive Lungenerkrankung (COPD)
Grundlagen, Risikofaktoren und Diagnose

Chronic Obstructive Pulmonary Disease: Basic Features, Risk Factors and DiagnosisD.  A.  Groneberg1 , H.  Golpon1 , T.  Welte1
  • 1Medizinische Hochschule Hannover, Abt. Pneumologie, Hannover
Further Information

Publication History

Publication Date:
16 November 2006 (online)

Also available at
   Permissions and Reprints

Lerninhalte

Grundlagenwissen zu Definition, Epidemiologie, Ätiologie und sozialökonomischer Bedeutung der COPD. Pathogenese, Pathologie, klinischer Verlauf und Klassifikation der stabilen COPD. Diagnose und Differenzialdiagnose der COPD. Differenzierte Beschreibung der diagnostischen Methoden und ihre Anwendung.

Literatur

  • 1 Worth H, Buhl R, Cegla U. et al . Leitlinien der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD).  Pneumologie. 2002;  56 704-738
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Pauwels R A, Buist A S, Calverley P MA. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  163 1256-1276
    CrossrefPubMedGoogle Scholar
  • 3 Lopez A D, Murray C JL. The global burden of disease, 1990 - 2020.  Nature Med. 1998;  4 1241-1243
    CrossrefPubMedGoogle Scholar
  • 4 Statistisches Bundesamt .Statistisches Jahrbuch, Jahrgänge 1968 - 1999. Stuttgart-Mainz
    Google Scholar
  • 5 Konietzko N, Fabel H. Weißbuch Lunge,. Stuttgart-New York: Thieme 2000
    Google Scholar
  • 6 Rychlik R, Pfeil T, Daniel D. et al . Zur sozioökonomischen Relevanz akuter Exacerbationen der chronischen Bronchitis in der Bundesrepublik Deutschland.  Dtsch Med Wschr. 2001;  126 353-359
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Groneberg D A, Chung K F. Models of chronic obstructive pulmonary disease.  Respir Res. 2004;  5 18-34
    CrossrefPubMedGoogle Scholar
  • 8 Wolkove N, Dacezman E, Colacone A. et al . The relationship between pulmonary function and dyspnoea in obstructive lung disease.  Chest. 1989;  96 1247-1251
    PubMedGoogle Scholar
  • 9 Begin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1991;  143 901-903
    PubMedGoogle Scholar
  • 10 O'Donnell D E, Forkert L, Webb K A. Evaluation of bronchodilator responses in patients with “irreversible” emphysema.  Eur Respir J. 2001;  18 914-920
    CrossrefPubMedGoogle Scholar
  • 11 Baldi S, Miniati M, Bellina C R. et al . Relationship between extent of pulmonary emphysema by high-resolution computed tomography and lung elastic recoil in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  169 585-589
    PubMedGoogle Scholar
  • 12 Georgopoulos D, Anthonisen N R. Symptoms and signs of COPD. In: Cherniack NS (ed). Chronic obstructive pulmonary disease. Toronto: Saunders 1991: 357-363
    Google Scholar
  • 13 Seemungal T A, Donaldson G C, Bhownik A. et al . Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2000;  161 1608-1613
    CrossrefPubMedGoogle Scholar
  • 14 Groneberg D A, Witt C, Kage A. O2-Partialdruck im Blut. In: Sinha P (ed). Laborbefunde und ihre klinischen Interpretationen. Balingen: Spitta Verlag
    Google Scholar
  • 15 Groneberg D A, Witt C, Kage A. CO2-Partialdruck im Blut. In: Sinha P (ed). Laborbefunde und ihre klinischen Interpretationen. Balingen: Spitta Verlag
    Google Scholar
  • 16 Roberts C M, Bugler J R, Melchor R. et al . Value of pulse oximetry for long-term oxygen therapy requirement.  Eur Respir J. 1993;  6 559-562
    CrossrefPubMedGoogle Scholar
  • 17 Groneberg D A, Witt C, Kage A. O2-Sättigung im Blut. In: Sinha P (ed). Laborbefunde und ihre klinischen Interpretationen. Balingen: Spitta Verlag
    Google Scholar
  • 18 Hughes J MB, Pride N B. In defense of the carbon monoxide transfer coefficent Kco(TL/VA).  Eur Respir J. 2001;  17 168-174
    CrossrefPubMedGoogle Scholar
  • 19 Gould G A, Redpath A T, Ryan M. et al . Lung CT density correlates with measurements of airflow limitation and the diffusing capacity.  Eur Respir J. 1991;  4 141-146
    PubMedGoogle Scholar
  • 20 Gevenois P A, de Vuyst P, de Maertelaer V. et al . Comparison of computed density and microscopic morphometry in pulmonary emphysema.  Am J Respir Crit Care Med. 1996;  154 187-192
    PubMedGoogle Scholar
  • 21 McLean A, Warren P M, Gilooly M. et al . Microscopic and macroscopic measurement of emphysema: relation to carbon monoxide transfer.  Thorax. 1992;  47 14-19
    PubMedGoogle Scholar
  • 22 Thurlbeck W M, Simon G. Radiographic appearance of the chest in emphysemas.  Am J Roentgenol. 1978;  130 429-440
    PubMedGoogle Scholar
  • 23 Morgan M DL, Denison D M, Stricklund B. Value of computed tomography for selecting patients with bullous emphysema.  Thorax. 1986;  41 855-862
    PubMedGoogle Scholar
  • 24 O'Donnell D E, Lam M, Webb K A. Spirometric correlates for improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1999;  160 542-549
    PubMedGoogle Scholar
  • 25 Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago “COPD” series.  Am Rev Respir Dis. 1989;  140 92-94
    PubMedGoogle Scholar
  • 26 Traver G A, Cline M G, Burrows B. Predictors of mortality in COPD.  Am Rev Respir Dis. 1979;  119 895-902
    PubMedGoogle Scholar
  • 27 Tweeddale P W, Alexander F, McHardy G JR. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects.  Thorax. 1987;  42 87-90
    PubMedGoogle Scholar
  • 28 Quanjer P H. Standardised lung function testing. Official statement of the European Respiratory Society.  Eur Respir J. 1993;  6 (Suppl 16) 5-40
    PubMedGoogle Scholar
  • 29 Berger R, Smith D. Effect of an inhaled metaproterenol on exercise performance in patients with stable “fixed” airway obstruction.  Am Rev Respir Dis. 1988;  138 626-629
    PubMedGoogle Scholar
  • 30 Guyatt G H, Townsend M, Pugsley S O. et al . Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity and quality of life.  Am Rev Respir Dis. 1987;  135 1069-1074
    PubMedGoogle Scholar
  • 31 Gross N, Tashkin D, Miller R. et al . Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.  Respiration. 1998;  65 354-362
    CrossrefPubMedGoogle Scholar
  • 32 Guyatt G H, Townsend M, Nogradi S. et al . Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation.  Arch Intern Med. 1988;  148 1949-1952
    CrossrefPubMedGoogle Scholar
  • 33 Callahan C M, Cirrus R S, Katz B P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis.  Ann Intern Med. 1991;  114 216-223
    PubMedGoogle Scholar
  • 34 Worth H, Adam D, Handrick W. et al . Prophylaxe und Therapie von bronchopulmonalen Infektionen. Empfehlungen der Deutschen Atemwegsliga.  Pneumologie. 1998;  52 232-237
    PubMedGoogle Scholar
  • 35 Niedermeier J, Barner A, Borst M. et al . Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Anwendung der Echokardiographie in der pneumologischen Diagnostik.  Pneumologie. 1998;  52 519-521
    PubMedGoogle Scholar
  • 36 Lehtonen J, Sutinen S, Ikaheimo M. et al . Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified at autopsy.  Chest. 1988;  93 839-842
    PubMedGoogle Scholar
  • 37 Cohen B, Ball Jr W, Brashears S. et al . Risk factors in chronic obstructive pulmonary disease (COPD).  Am J Epidemiol. 1977;  105 223-232
    PubMedGoogle Scholar
  • 38 Cohen B, Bias W, Chase G. et al . Is ABH nonsecretor status a risk factor for obstructive lung disease?.  Am J Epidemiol. 1980;  111 285-291
    PubMedGoogle Scholar
  • 39 Kauffmann F, Frette C, Pham Q. et al . Associations of blood group-related antigens to FEV1, wheezing, and asthma.  Am J Respir Crit Care Med. 1996;  153 76-82
    PubMedGoogle Scholar
  • 40 Tobin M J, Cook P J, Hutchison D C. α1-antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association.  Br J Dis Chest. 1983;  77 14-27
    CrossrefPubMedGoogle Scholar
  • 41 Larsson C. Natural history and life expectancy in severe α1-antitrypsin deficiency, Pi Z.  Acta Med Scand. 1978;  204 345-351
    PubMedGoogle Scholar
  • 42 Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe α1-antitrypsin deficiency (PiZZ).  Eur Respir J. 1999;  13 247-251
    CrossrefPubMedGoogle Scholar
  • 43 Silverman E K, Pierce J A, Province M A. et al . Variability of pulmonary function in α1-antitrypsin deficiency: clinical correlates.  Ann Intern Med. 1989;  111 982-991
    PubMedGoogle Scholar
  • 44 Silverman E K, Province M A, Campbell E J. et al . Family study of α1-antitrypsin deficiency: effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits.  Genet Epidemiol. 1992;  9 317-331
    CrossrefPubMedGoogle Scholar
  • 45 Seersholm N, Kok-Jensen A, Dirksen A. Decline in FEV1 among patients with severe hereditary α1-antitrypsin deficiency type PiZ.  Am J Respir Crit Care Med. 1995;  152 1922-1925
    PubMedGoogle Scholar
  • 46 Seersholm N, Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary α1-antitrypsin deficiency.  Am J Respir Crit Care Med. 1995;  151 369-373
    CrossrefPubMedGoogle Scholar
  • 47 Black L F, Kueppers F. α1-Antitrypsin deficiency in nonsmokers.  Am Rev Respir Dis. 1978;  117 421-428
    PubMedGoogle Scholar
  • 48 Piitulainen E, Tornling G, Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe α1-antitrypsin deficiency (PiZZ).  Thorax. 1998;  53 939-943
    PubMedGoogle Scholar
  • 49 Mayer A S, Stoller J K, Bartelson B B. et al . Occupational Exposure Risks in Individuals with PI*Z α-1-Antitrypsin Deficiency.  Am J Respir Crit Care Med. 2000;  162 553-558
    PubMedGoogle Scholar
  • 50 Benetazzo M G, Gile L S, Bombieri C. et al . α-1-antitrypsin TAQ I polymorphism and α-1-antichymotrypsin mutations in patients with obstructive pulmonary disease.  Respir Med. 1999;  93 648-654
    CrossrefPubMedGoogle Scholar
  • 51 Poller W, Faber J P, Scholz S. et al . Missense mutation of α-1-antichymotrypsin gene associated with chronic lung disease.  Lancet. 1992;  339 1538
    PubMedGoogle Scholar
  • 52 Sandford A J, Chagani T, Weir T D. et al . α-1-antichymotrypsin mutations in patients with chronic obstructive pulmonary disease.  Dis Markers. 1998;  13 257-260
    PubMedGoogle Scholar
  • 53 Ishii T, Matsuse T, Teramoto S. et al . Association between α-1-antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary disease.  Eur J Clin Invest. 2000;  30 543-548
    CrossrefPubMedGoogle Scholar
  • 54 Minematsu N, Nakamura H, Iwata M. et al . Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema.  Thorax. 2003;  58 623-628
    CrossrefPubMedGoogle Scholar
  • 55 Pignatti P F, Bombieri C, Benetazzo M. et al . CFTR gene variant IVS8 - 5T in disseminated bronchiectasis.  Am J Hum Genet. 1996;  58 889-892
    PubMedGoogle Scholar
  • 56 Bombieri C, Benetazzo M, Saccomani A. et al . Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease.  Hum Genet. 1998;  103 718-722
    CrossrefPubMedGoogle Scholar
  • 57 Tzetis M, Efthymiadou A, Strofalis S. et al . CFTR gene mutations - including three novel nucleotide substitutions - and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease.  Hum Genet. 2001;  108 216-221
    CrossrefPubMedGoogle Scholar
  • 58 Yim J-J, Park G Y, Lee C-T. et al . Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1.  Thorax. 2000;  55 121-125
    CrossrefPubMedGoogle Scholar
  • 59 Harrison D J, Cantlay A M, Rae F. et al . Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer.  Hum Exp Toxicol. 1997;  16 356-360
    CrossrefPubMedGoogle Scholar
  • 60 Baranova H, Perriot J, Albuisson E. et al . Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis.  Hum Genet. 1997;  99 822-826
    CrossrefPubMedGoogle Scholar
  • 61 Ishii T, Matsuse T, Teramoto S. et al . Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease.  Thorax. 1999;  54 693-696
    CrossrefPubMedGoogle Scholar
  • 62 Yamada N, Yamaya M, Okinaga S. et al . Microsatellite polymorphism in the heme oxygenase-1-gene promoter is associated with susceptibility to emphysema.  Am J Hum Genet. 2000;  66 187-195
    CrossrefPubMedGoogle Scholar
  • 63 Kauffmann F, Kleisbauer J P, Cambon-De-Mouzon A. et al . Genetic markers in chronic air-flow limitation. A genetic epidemiologic study.  Am Rev Respir Dis. 1983;  127 263-269
    PubMedGoogle Scholar
  • 64 Sugiyama Y, Kudoh S, Maeda H. et al . Analysis of HLA antigens in patients with diffuse panbronchiolitis.  Am Rev Respir Dis. 1990;  141 1459-1462
    CrossrefPubMedGoogle Scholar
  • 65 Keicho N, Tokunaga K, Nakata K. et al . Contribution of HLA Genes to Genetic Predisposition in Diffuse Panbronchiolitis.  Am J Respir Crit Care Med. 1998;  158 846-850
    CrossrefPubMedGoogle Scholar
  • 66 Bjorkander J, Bake B, Oxelius V. et al . Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3.  N Engl J Med. 1985;  313 720-724
    PubMedGoogle Scholar
  • 67 O'Keeffe S, Gzel A, Drury R. et al . Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease.  Eur Respir J. 1991;  4 932-936
    PubMedGoogle Scholar
  • 68 Webb D R, Condemi J J. Selective immunoglobulin A deficiency and chronic obstructive lung disease. A family study.  Ann Intern Med. 1974;  80 618-621
    PubMedGoogle Scholar
  • 69 Smith C A, Harrison D J. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema.  Lancet. 1997;  350 630-633
    CrossrefPubMedGoogle Scholar
  • 70 Yoshikawa M, Hiyama K, Ishioka S. et al . Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese.  Int J Mol Med. 2000;  5 49-53
    PubMedGoogle Scholar
  • 71 Sandford A J, Chagani T, Weir T D. et al . Susceptibility Genes for Rapid Decline of Lung Function in the Lung Health Study.  Am J Respir Crit Care Med. 2001;  163 469-473
    CrossrefPubMedGoogle Scholar
  • 72 Bouma G, Crusius J B, Oudkerk Pool M. et al . Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease.  Scand J Immunol. 1996;  43 456-463
    CrossrefPubMedGoogle Scholar
  • 73 Huang S-L, Su C-H, Chang S-C. Tumor Necrosis Factor-alpha Gene Polymorphism in Chronic Bronchitis.  Am J Respir Crit Care Med. 1997;  156 1436-1439
    CrossrefPubMedGoogle Scholar
  • 74 Sakao S, Tatsumi K, Igari H. et al . Association of Tumor Necrosis Factor {α} Gene Promoter Polymorphism with the Presence of Chronic Obstructive Pulmonary Disease.  Am J Respir Crit Care Med. 2001;  163 420-422
    CrossrefPubMedGoogle Scholar
  • 75 Ishii T, Matsuse T, Teramoto S. et al . Neither IL-1β, IL-1 receptor antagonist, nor TNF-α polymorphisms are associated with susceptibility to COPD.  Respir Med. 2000;  94 847-851
    PubMedGoogle Scholar
  • 76 Higham M A, Pride N B, Alikhan A. et al . Tumour necrosis factor-α gene promoter polymorphism in chronic obstructive pulmonary disease.  Eur Respir J. 2000;  15 281-284
    CrossrefPubMedGoogle Scholar
  • 77 Horne S L, Cockcroft D W, Dosman J A. Possible protective effect against chronic obstructive airways disease by the GC2 allele.  Hum Hered. 1990;  40 173-176
    CrossrefPubMedGoogle Scholar
  • 78 Schellenberg D, Pare P D, Weir T D. et al . Vitamin D Binding Protein Variants and the Risk of COPD.  Am J Respir Crit Care Med. 1998;  157 957-961
    CrossrefPubMedGoogle Scholar
  • 79 Springer J, Scholz F R, Peiser C. et al . SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitory SMAD 6 and 7 by cigarette smoke.  Biol Chem. 2004;  385 649-653
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. T. Welte

Medizinische Hochschule Hannover · Abt. Pneumologie

Carl-Neuberg-Str. 1

30625 Hannover

Email: Welte.Tobias@mh-hannover.de

      >